pharmaphorum

MAY 16, 2022

Adele Waugaman, senior digital health coordinator of the COVID-19 response at the United States Agency for International Development (USAID), tells us what the agency focuses on to strengthen digital health infrastructure globally and improve and expand healthcare access. USAID learned a great deal from the Ebola outbreak in West Africa concerning effective digital health distribution and strategies for digital health implementation that were then applied to its COVID-19 response globally – alth

Documentation 116

Documentation Vaccines 116

Outsourcing Pharma

MAY 16, 2022

The companyâs analysis of 2.5m patients worldwide suggest a growing proportion of younger patients, with implications for future study design and deployment.

69

69

pharmaphorum

MAY 16, 2022

Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check. Eli Lilly’s Mounjaro (tirzepatide) was given the green light by the US Food and Drug Administration after the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 glucagon-like peptide-1 (GLP-1 ) receptor agonist showed its effectiveness when used in conjunction with diet and exercise.

FDA 113

FDA 113

The Happy PharmD

MAY 16, 2022

We have all been at various points in our lives where we felt we have had enough and desired a change. It could be breaking free from an addiction, deciding to start a family, or in this case leaving a job where you have been unhappy and stressed. However, a few days or weeks down the line, we end up not following our action plan or even fail to draft out one.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 16, 2022

A digital health startup accelerator is launching in Italy, with more than €6 million backing the new enterprise. Called VITA, the accelerator will support up to 10 startups focused on digital transformation of the health system. The project is backed by asset management company CDP Venture Capital SGR, with help from digital health consultancy Healthware Group (pharmaphorum’s parent company) and Danish accelerator Accelerace.

Hospitals 109

Hospitals 109

Outsourcing Pharma

MAY 16, 2022

The cancer trial-matching company is partnering with MPN Research Foundation to help match patients with a group of rare blood cancers to clinical trials.

52

52

Outsourcing Pharma

MAY 16, 2022

Novartis has recently set up a new contract development and manufacturing unit called Global Biotech Co-operations (GBTC).

52

52

Pharma Times

MAY 16, 2022

Sarclisa is a monoclonal antibody which targets a specific epitope on the CD38 receptor on multiple myeloma cells

41

41

pharmaphorum

MAY 16, 2022

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator. Inmagene Pharma’s investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, can now proceed to a phase 1 clinical trial, following the green light from the US Food and Drug Administration.

Immunization 52

Immunization FDA 52

Pharma Times

MAY 16, 2022

PT027 is being developed through a partnership involving AstraZeneca and Avillion

39

39

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA